• From Ribosomes to Liver Fibrosis: A Translational Lens

  2026-09-24

  Tetracycline is best understood as a bacterial ribosome tool—not a shortcut for probing mammalian ER stress. This article connects its mechanistic value in microbiology with findings on QRICH1 and HMGB1 in HBV-associated liver fibrosis, while outlining practical controls, translational boundaries, and research decisions that strengthen interpretation.

• (Z)-4-Hydroxytamoxifen: Reliable ER Assays

  2026-09-23

  Learn how (Z)-4-Hydroxytamoxifen (SKU B5421) can improve experimental control in estrogen receptor, viability, proliferation, and cytotoxicity workflows. This scenario-based guide connects formulation, assay design, data interpretation, and breast cancer relapse research.

• Ciclesonide: Lung Activation and ERAD Assay Logic

  2026-09-22

  Ciclesonide is a lung-activated glucocorticoid prodrug with distinctive value in asthma treatment research. This article separates its validated respiratory pharmacology from emerging ERAD-hijacking methods and translates both into clearer assay decisions.

• Romidepsin: Workflow for HDAC Mechanism Studies

  2026-09-22

  Romidepsin (FK228) combines class I HDAC selectivity with practical utility in chromatin, cell-cycle, and apoptosis assays. This workflow shows how to connect dose-response experiments with proteomics-inspired target-engagement studies while avoiding unsupported claims about unrelated signaling targets.

• Curcumol, SAM, and Autophagy in Liver Fibrosis

  2026-09-21

  A 2026 study links curcumol-induced hepatic stellate cell death to disruption of methionine metabolism, placing MAT2A, AHCY, and S-adenosylmethionine within an autophagy-related antifibrotic mechanism. Pharmacological inhibition, ATG7 silencing, and SAM rescue experiments provide a useful framework for separating correlation from functional pathway involvement in liver fibrosis research.

• Imatinib Hydrochloride: A New Kinase Question

  2026-09-21

  Imatinib hydrochloride remains a powerful model for studying oncogenic tyrosine kinase signaling, but emerging phosphatase research suggests that catalytic inhibition may be only one layer of biological control. This article translates that insight into a practical, translational workflow for chronic myelogenous leukemia and gastrointestinal stromal tumor research while distinguishing established evidence from testable hypotheses.

• 2-NBDG Glucose Uptake Assay Kit Guide

  2026-09-20

  This scenario-based guide explains how SKU K2212 supports reproducible, non-radioactive measurement of cellular glucose uptake in viability, cytotoxicity, and metabolism studies. It covers assay principle, controls, 96-well workflow design, interpretation limits, and practical product-selection criteria.

• KR-12 (human) TFA: Reliable Assay Design

  2026-09-19

  Learn how KR-12 (human) TFA, SKU C8754, can support better-controlled antimicrobial, viability, proliferation, and cytotoxicity workflows. This scenario-based guide connects peptide formulation, concentration planning, assay controls, and interpretation to published KR-12 biology.

• Mechanical Stress, Cytoskeleton, and Autophagy

  2026-09-19

  The reference study shows that autophagy induced by cellular compression depends primarily on cytoskeletal microfilaments, while microtubules provide supporting functions. Its combined use of mechanical loading, cytoskeletal perturbation, fluorescence imaging, and western blotting offers a practical framework for dissecting force-dependent autophagy and mechanotransduction.

• AS1842856 Foxo1 Inhibitor: Mechanism & Workflow

  2026-09-18

  AS1842856 is a Foxo1 inhibitor reported to reduce Foxo1 activity without lowering Foxo1 protein abundance. Its documented effects on gluconeogenic gene expression, hepatic glucose production, and autophagy-related activity support controlled metabolic and type 2 diabetes research workflows.

• RGFP966: From HDAC3 Modulation to HO-1 Insight

  2026-09-17

  RGFP966 can serve as a mechanistic perturbation tool for testing how HDAC3-linked regulation intersects with HO-1 enzyme activity. Paired with the AMC-Hem activity probe described in the reference study, it supports a translational workflow that separates HO-1 abundance from catalytic function in macrophage and vascular research.

• Platycodin D Targets RFC4 in Lung Cancer

  2026-09-17

  This pre-proof study combines thermal proteome profiling, local stability mapping, and proteomic analyses to identify RFC4 as a candidate binding target of Platycodin D in non-small cell lung cancer. Its findings connect RFC4 engagement with reduced Notch1/Notch3 signaling, altered ubiquitination, and apoptosis, providing a target-to-pathway framework for mechanistic drug research.

• CAY10499: Mapping Lipid Hydrolysis in TAMs

  2026-09-16

  CAY10499, an inhibitor of human hormone sensitive lipase and monoglyceride lipase, can help separate lipid hydrolysis from ACLY-driven fatty-acid synthesis in macrophage studies. This article develops an assay strategy for interpreting tumor-associated macrophage metabolism without conflating mechanistically distinct lipid pathways.

• EZ Cap™ Cas9 mRNA (5-moUTP) Workflow Guide

  2026-09-16

  Build transient CRISPR-Cas9 genome editing workflows for zebrafish neurodegeneration and cell-based functional gene studies with a capped, modified Cas9 mRNA. This guide connects the Fyn–Stat3 neurodegeneration model to practical delivery, control, optimization, and troubleshooting decisions.

• Moxifloxacin Workflows for Gyrase and Toxicity

  2026-09-15

  Moxifloxacin supports a connected workflow spanning bacterial DNA gyrase studies, mammalian cell viability assays, and antibiotic-associated metabolic research. This guide translates the product’s physicochemical profile and the reference study’s topoisomerase findings into practical assay design, controls, and troubleshooting decisions.

3605 records 1/241 page Next 12345 下5页 Last page